Abstract
The most frequent special histological type of breast cancer is represented by invasive lobular carcinoma (ILC), which makes up about 15% of all invasive breast carcinomas. The molecular signature of ILC is the dysregulation of E-cadherin due to CDH1 abnormalities. Although CDH1 germline mutations are very uncommon in women with early-onset and/or familial ILC, they are the most common detrimental non-BRCA mutations and are thought to be the origin of a significant fraction of lobular breast cancer. Since the morphology and immunophenotype of hereditary and non-hereditary ILCs are nearly identical, no specific histopathological findings can be used to distinguish between the two. High-throughput sequencing studies revealed that ILCs represent a separate entity at the genomic level. This chapter addresses the very important topic of ILC morpho-molecular characteristics in the setting of germline and/or somatic CDH1 abnormalities.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Breast Tumours (2019) WHO Classification of Tumours. International Agency for Research on Cancer
Pereira B, Chin SF, Rueda OM et al (2016) The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 7:11479
Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506–519
Grote I, Bartels S, Christgen H et al (2022) ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. Mod Pathol
WHO Classification of Tumours Editorial Board (2019) WHO classification of breast tumours: WHO classification of tumours, vol 2. World Health Organization
Ross JS, Wang K, Sheehan CE et al (2013) Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 19:2668–2676
Corso G, Montagna G, Figueiredo J et al (2020) Hereditary gastric and breast cancer syndromes related to CDH1 germline mutation: a multidisciplinary clinical review. Cancers (Basel) 12
Desmedt C, Zoppoli G, Gundem G et al (2016) Genomic characterization of primary invasive lobular breast cancer. J Clin Oncol 34:1872–1881
Guiu S, Wolfer A, Jacot W et al (2014) Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? Crit Rev Oncol Hematol 92:235–257
Chen Z, Yang J, Li S et al (2017) Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS One 12:e0182397
McCart Reed AE, Kutasovic JR, Lakhani SR et al (2015) Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res 17:12
Pagni F, Guerini-Rocco E, Schultheis AM et al (2019) Targeting immune-related biological processes in solid tumors: we do need biomarkers. Int J Mol Sci 20
Arias-Stella JA, Alvarado-Cabrero I, Pareja F (2018) Special types of invasive breast carcinoma. Practical Atlas of breast pathology. Springer, pp 263–292
Walker RA, Hanby A, Pinder SE et al (2012) Current issues in diagnostic breast pathology. J Clin Pathol 65:771–785
De Schepper M, Vincent-Salomon A, Christgen M et al (2022) Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer. Mod Pathol
Christgen M, Cserni G, Floris G et al (2021) Lobular breast cancer: histomorphology and different concepts of a special spectrum of tumors. Cancers (Basel) 13
Fusco N, Sajjadi E, Venetis K et al (2022) Low-risk triple-negative breast cancers: clinico-pathological and molecular features. Crit Rev Oncol Hematol 103643
Venetis K, Crimini E, Sajjadi E, et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci 2022:fmolb.2022.834651
Conforti F, Pala L, Pagan E et al (2019) Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Res 21:153
Iorfida M, Maiorano E, Orvieto E et al (2012) Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 133:713–723
Thompson ED, Taube JM, Asch-Kendrick RJ et al (2017) PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Mod Pathol 30:1551–1560
Dill EA, Gru AA, Atkins KA et al (2017) PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am J Surg Pathol 41:334–342
Desmedt C, Salgado R, Fornili M et al (2018) Immune infiltration in invasive lobular breast cancer. J Natl Cancer Inst 110:768–776
Sobral-Leite M, Van de Vijver K, Michaut M et al (2018) Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Onco Targets Ther 7:e1509820
Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105–2122
Tarantino P, Hamilton E, Tolaney SM et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38:1951–1962
Venetis K, Crimini E, Sajjadi E et al (2022) HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci 9:834651
Sajjadi E, Venetis K, Ivanova M et al (2022) Improving HER2 testing reproducibility in HER2-low breast cancer. Cancer Drug Resist 5 (Accepted)
Mutai R, Barkan T, Moore A et al (2021) Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. Breast 60:62–69
Tarantino P, Jin Q, Tayob N et al (2022) Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol
Lopez-Garcia MA, Geyer FC, Lacroix-Triki M et al (2010) Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 57:171–192
Sciarra A, Lopez G, Corti C et al (2019) Columnar cell lesion and apocrine hyperplasia of the breast: is there a common origin? The role of prolactin-induced protein. Appl Immunohistochem Mol Morphol 27:508–514
Guerini-Rocco E, Fusco N (2017) Premalignant and preinvasive lesions of the breast. In: Veronesi U, Goldhirsh A, Veronesi P et al (eds) Breast cancer: innovations in research and management. Springer International Publishing, pp 103–120
Sciarra A, Lopez G, Corti C, et al (2017) Columnar cell lesion and apocrine hyperplasia of the breast: is there a common origin? The role of prolactin-induced protein. Appl Immunohistochem Mol Morphol
Sakr RA, Schizas M, Carniello JV et al (2016) Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: repertoire of somatic genetic alterations and clonal relationships. Mol Oncol 10:360–370
Lee JY, Schizas M, Geyer FC et al (2019) Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma. Clin Cancer Res 25:674–686
Girardi A, Magnoni F, Vicini E et al (2022) CDH1 germline mutations in families with hereditary lobular breast cancer. Eur J Cancer Prev 31:274–278
Massari G, Magnoni F, Favia G et al (2021) Frequency of CDH1 germline mutations in non-gastric cancers. Cancers (Basel) 13
Paço A, Leitão-Castro J, Freitas R (2021) Epigenetic regulation of CDH1 is altered after HOXB7-silencing in MDA-MB-468 triple-negative breast cancer cells. Genes (Basel) 12
Halbleib JM, Nelson WJ (2006) Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 20:3199–3214
Paredes J, Figueiredo J, Albergaria A et al (2012) Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 1826:297–311
Corso G (2022) Pleiotropic cancer manifestations of germline CDH1 mutations: risks and management. J Surg Oncol 125:1326–1331
Rätze MAK, Koorman T, Sijnesael T et al (2022) Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. Oncogene 41:2932–2944
Arps DP, Healy P, Zhao L et al (2013) Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast. Breast Cancer Res Treat 138:719–726
Christgen M, Kandt LD, Antonopoulos W et al (2022) Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. J Pathol Clin Res 8:191–205
Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404
Luo W, Fedda F, Lynch P et al (2018) CDH1 gene and hereditary diffuse gastric cancer syndrome: molecular and histological alterations and implications for diagnosis and treatment. Front Pharmacol 9:1421
Park JW, Jang SH, Park DM et al (2014) Cooperativity of E-cadherin and Smad4 loss to promote diffuse-type gastric adenocarcinoma and metastasis. Mol Cancer Res 12:1088–1099
Park JW, Kim M-S, Voon DC et al (2018) Multi-omics analysis identifies pathways and genes involved in diffuse-type gastric carcinogenesis induced by E-cadherin, p53, and Smad4 loss in mice. Mol Carcinog 57:947–954
Corso G, Figueiredo J, De Angelis SP et al (2020) E-cadherin deregulation in breast cancer. J Cell Mol Med 24:5930–5936
Shargh SA, Sakizli M, Khalaj V et al (2014) Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol 31:250
Shinozaki M, Hoon DS, Giuliano AE et al (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11:2156–2162
Sebova K, Zmetakova I, Bella V et al (2011) RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark 10:13–26
Liu J, Sun X, Qin S et al (2016) CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer. Oncol Lett 11:2635–2643
Schmalhofer O, Brabletz S, Brabletz T (2009) E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28:151–166
Bolós V, Peinado H, Pérez-Moreno MA et al (2003) The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with snail and E47 repressors. J Cell Sci 116:499–511
Peinado H, Ballestar E, Esteller M et al (2004) Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 24:306–319
Comijn J, Berx G, Vermassen P et al (2001) The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7:1267–1278
Figueiredo J, Melo S, Carneiro P et al (2019) Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet 56:199–208
Li M, Rao X, Cui Y et al (2021) The keratin 17/YAP/IL6 axis contributes to E-cadherin loss and aggressiveness of diffuse gastric cancer. Oncogene
Xiang S, Liu YM, Chen X et al (2015) ZEB1 expression is correlated with tumor metastasis and reduced prognosis of breast carcinoma in Asian patients. Cancer Investig 33:225–231
Qian X, Karpova T, Sheppard AM et al (2004) E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 23:1739–1748
Pece S, Gutkind JS (2000) Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation. J Biol Chem 275:41227–41233
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454
Gottardi CJ, Wong E, Gumbiner BM (2001) E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol 153:1049–1060
Nelson WJ, Nusse R (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303:1483–1487
Deplazes J, Fuchs M, Rauser S et al (2009) Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Hum Mol Genet 18:3632–3644
Bruner HC, Derksen PWB (2018) Loss of E-cadherin-dependent cell-cell adhesion and the development and progression of cancer, vol 10. Cold Spring Harb Perspect Biol
Vlahopoulos SA, Cen O, Hengen N et al (2015) Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment. Cytokine Growth Factor Rev 26:389–403
Munshi HG, Ghosh S, Mukhopadhyay S et al (2002) Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes. J Biol Chem 277:38159–38167
Davies G, Jiang WG, Mason MD (2001) Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 7:3289–3297
Ferreira AC, Suriano G, Mendes N et al (2012) E-cadherin impairment increases cell survival through notch-dependent upregulation of Bcl-2. Hum Mol Genet 21:334–343
Christinat A, Pagani O (2013) Practical aspects of genetic counseling in breast cancer: lights and shadows. Breast 22:375–382
Stephens PJ, Tarpey PS, Davies H et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400–404
The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
Curtis C, Shah SP, Chin SF et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352
Ellis MJ, Perou CM (2013) The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 3:27–34
Corso G, Veronesi P, Sacchini V et al (2018) Prognosis and outcome in CDH1-mutant lobular breast cancer. Eur J Cancer Prev 3:237–238
Bareche Y, Venet D, Ignatiadis M et al (2018) Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 29:895–902
Conforti F, Pala L, Pagan E et al (2021) Biological and clinical features of triple negative invasive lobular carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast 59:94–101
Pareja F, Ferrando L, Lee SSK et al (2020) The genomic landscape of metastatic histologic special types of invasive breast cancer. NPJ Breast Cancer 6:53
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Porta, F.M., Blanco, M.C., Ivanova, M., Fusco, N., Guerini-Rocco, E. (2023). Pathology and Somatic Alterations in Hereditary Lobular Breast Cancers. In: Corso, G., Veronesi, P., Roviello, F. (eds) Hereditary Gastric and Breast Cancer Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-031-21317-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-031-21317-5_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-21316-8
Online ISBN: 978-3-031-21317-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)